Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Abstract Background Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinical management of patients. Methods Plasma s...

Full description

Bibliographic Details
Main Authors: Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, Mélanie Delaunoy, Hakim El Housni, Gil Awada, Julia Katharina Schwarze, Marleen Keyaerts, Hendrik Everaert, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Journal of Translational Medicine
Subjects:
Translational research
Liquid biopsy
Circulating tumor DNA
Monitoring
Immunotherapy
Metastatic melanoma
Online Access:http://link.springer.com/article/10.1186/s12967-019-2051-8

Internet

http://link.springer.com/article/10.1186/s12967-019-2051-8

Similar Items